## 10th Mayo Clinic Symposium on Tumor Microenvironment and Immuno-Oncology Crosstalk:

From Novel Therapeutics to transformative practice

## Ponte Vedra Inn and Club Ponte Vedra Beach, Florida

**December 5-7, 2024** 

## All Presentations Eastern Time

7:00 a.m. Breakfast and Registration 8:00 a.m. Section I: Mini-Symposium – Nanotechnology and System Biology Chairs: Priyabrata Mukherjee, Ph.D., Stephenson Cancer Center 8:10 a.m. Harnessing nano properties to improve cancer immunotherapy. Andrew Wang, M.D., UT Southwestern Medical Center 8:30 a.m. Discussion 8:35 a.m. Biomimetic Microbubbles- A Novel Delivery Platform for Immunotherapy and Imaging Ramasamy Paulmurugan, Ph.D., Stanford University 8:55 a.m. Discussion 9:00 a.m. Nanoparticles encapsulated with drugs to reduce stenosis formation in hemodialysis vascular access Gaurav Sahai, Ph.D., Oregon State University 9:20 a.m. Discussion 9:25 a.m. Title TBA Liangfang Zhang, Ph.D., UC San Diego 9:45 a.m. Discussion 9:50 a.m. Title TBA Priyabrata Mukhherjee, Ph.D., Stephenson Cancer Center, Oklahoma 10:10 a.m. Discussion 10:15 a.m. Coffee Break and Exhibits 10:45 a.m. Continuous low-dose cancer chemotherapy with oral nanoparticle-paclitaxel Dipanjan Pan, Ph.D., Pennsylvania State University 11:05 a.m. Discussion 11:30 a.m. Discussion 11:30 a.m. Discussion 11:30 a.m. Discussion 11:35 a.m. Title TBA Zigang Dong, M.D., Ph.D., China-US(Henan) Hormel Cancer Institute, University of Zhengzhou 11:55 a.m. Discussion	Thursday, December 5, 2024		
Chairs: Priyabrata Mukherjee, Ph.D., Stephenson Cancer Center  8:10 a.m. Harnessing nano properties to improve cancer immunotherapy. Andrew Wang, M.D., UT Southwestern Medical Center  8:30 a.m. Discussion  8:35 a.m. Biomimetic Microbubbles- A Novel Delivery Platform for Immunotherapy and Imaging Ramasamy Paulmurugan, Ph.D., Stanford University  8:55 a.m. Discussion  9:00 a.m. Nanoparticles encapsulated with drugs to reduce stenosis formation in hemodialysis vascular access Gaurav Sahai, Ph.D., Oregon State University  9:20 a.m. Discussion  9:25 a.m. Title TBA Liangfang Zhang, Ph.D., UC San Diego  9:45 a.m. Discussion  9:50 a.m. Title TBA Priyabrata Mukhherjee, Ph.D., Stephenson Cancer Center, Oklahoma  10:10 a.m. Discussion  10:15 a.m. Coffee Break and Exhibits  10:45 a.m. Continuous low-dose cancer chemotherapy with oral nanoparticle-paclitaxel Dipanjan Pan, Ph.D., Pennsylvania State University  11:05 a.m. Discussion  11:10 a.m. Ex vivo vulnerabilities of human gliomas Sunil Krishnan, M.D., Ph.D., UT Health Houston  11:35 a.m. Title TBA Zigang Dong, M.D., Ph.D., China-US(Henan) Hormel Cancer Institute, University of Zhengzhou  11:55 a.m. Discussion	7:00 a.m.	Breakfast and Registration	
8:10 a.m. Harnessing nano properties to improve cancer immunotherapy. Andrew Wang, M.D., UT Southwestern Medical Center  8:30 a.m. Discussion  8:35 a.m. Biomimetic Microbubbles- A Novel Delivery Platform for Immunotherapy and Imaging Ramasamy Paulmurugan, Ph.D., Stanford University  8:55 a.m. Discussion  9:00 a.m. Nanoparticles encapsulated with drugs to reduce stenosis formation in hemodialysis vascular access Gaurav Sahai, Ph.D., Oregon State University  9:20 a.m. Discussion  9:25 a.m. Title TBA Liangfang Zhang, Ph.D., UC San Diego  9:45 a.m. Discussion  9:50 a.m. Title TBA Priyabrata Mukhherjee, Ph.D., Stephenson Cancer Center, Oklahoma  10:10 a.m. Discussion  10:15 a.m. Coffee Break and Exhibits  10:45 a.m. Continuous low-dose cancer chemotherapy with oral nanoparticle-paclitaxel Dipanjan Pan, Ph.D., Pennsylvania State University  11:05 a.m. Discussion  11:10 a.m. Ex vivo vulnerabilities of human gliomas Sunil Krishnan, M.D., Ph.D., UT Health Houston  11:35 a.m. Title TBA Zigang Dong, M.D., Ph.D., China-US(Henan) Hormel Cancer Institute, University of Zhengzhou  11:55 a.m. Discussion	8:00 a.m.	Section I: Mini-Symposium – Nanotechnology and System Biology	
Andrew Wang, M.D., UT Southwestern Medical Center  8:30 a.m. Discussion  8:35 a.m. Biomimetic Microbubbles- A Novel Delivery Platform for Immunotherapy and Imaging Ramasamy Paulmurugan, Ph.D., Stanford University  8:55 a.m. Discussion  9:00 a.m. Nanoparticles encapsulated with drugs to reduce stenosis formation in hemodialysis vascular access Gaurav Sahai, Ph.D., Oregon State University  9:20 a.m. Discussion  9:25 a.m. Title TBA Liangfang Zhang, Ph.D., UC San Diego  9:45 a.m. Discussion  9:50 a.m. Title TBA Priyabrata Mukhherjee, Ph.D., Stephenson Cancer Center, Oklahoma  10:10 a.m. Discussion  10:15 a.m. Coffee Break and Exhibits  10:45 a.m. Continuous low-dose cancer chemotherapy with oral nanoparticle-paclitaxel Dipanjan Pan, Ph.D., Pennsylvania State University  11:05 a.m. Discussion  11:10 a.m. Ex vivo vulnerabilities of human gliomas Sunil Krishnan, M.D., Ph.D., UT Health Houston  11:35 a.m. Title TBA Zigang Dong, M.D., Ph.D., China-US(Henan) Hormel Cancer Institute, University of Zhengzhou  11:55 a.m. Discussion			
8:30 a.m. Discussion 8:35 a.m. Biomimetic Microbubbles- A Novel Delivery Platform for Immunotherapy and Imaging Ramasamy Paulmurugan, Ph.D., Stanford University 9:00 a.m. Discussion 9:20 a.m. Nanoparticles encapsulated with drugs to reduce stenosis formation in hemodialysis vascular access Gaurav Sahai, Ph.D., Oregon State University 9:20 a.m. Discussion 9:25 a.m. Title TBA Liangfang Zhang, Ph.D., UC San Diego 9:45 a.m. Discussion 9:50 a.m. Title TBA Priyabrata Mukhherjee, Ph.D., Stephenson Cancer Center, Oklahoma 10:10 a.m. Discussion 10:15 a.m. Coffee Break and Exhibits 10:45 a.m. Continuous low-dose cancer chemotherapy with oral nanoparticle-paclitaxel Dipanjan Pan, Ph.D., Pennsylvania State University 11:05 a.m. Discussion 11:10 a.m. Ex vivo vulnerabilities of human gliomas Sunil Krishnan, M.D., Ph.D., UT Health Houston 11:35 a.m. Title TBA Zigang Dong, M.D., Ph.D., China-US(Henan) Hormel Cancer Institute, University of Zhengzhou 11:55 a.m. Discussion	8:10 a.m.		
8:35 a.m. Biomimetic Microbubbles- A Novel Delivery Platform for Immunotherapy and Imaging Ramasamy Paulmurugan, Ph.D., Stanford University  8:55 a.m. Discussion  9:00 a.m. Nanoparticles encapsulated with drugs to reduce stenosis formation in hemodialysis vascular access Gaurav Sahai, Ph.D., Oregon State University  9:20 a.m. Discussion  9:25 a.m. Title TBA Liangfang Zhang, Ph.D., UC San Diego  9:45 a.m. Discussion  9:50 a.m. Title TBA Priyabrata Mukhherjee, Ph.D., Stephenson Cancer Center, Oklahoma  10:10 a.m. Discussion  10:15 a.m. Coffee Break and Exhibits  10:45 a.m. Continuous low-dose cancer chemotherapy with oral nanoparticle-paclitaxel Dipanjan Pan, Ph.D., Pennsylvania State University  11:05 a.m. Discussion  11:30 a.m. Discussion  11:30 a.m. Discussion  11:35 a.m. Title TBA Zigang Dong, M.D., Ph.D., China-US(Henan) Hormel Cancer Institute, University of Zhengzhou  Discussion			
Ramasamy Paulmurugan, Ph.D., Stanford University  8:55 a.m.  Discussion  Nanoparticles encapsulated with drugs to reduce stenosis formation in hemodialysis vascular access Gaurav Sahai, Ph.D., Oregon State University  9:20 a.m.  Discussion  9:25 a.m.  Title TBA  Liangfang Zhang, Ph.D., UC San Diego  9:45 a.m.  Discussion  7:tle TBA  Priyabrata Mukhherjee, Ph.D., Stephenson Cancer Center, Oklahoma  10:10 a.m.  Discussion  10:15 a.m.  Coffee Break and Exhibits  Continuous low-dose cancer chemotherapy with oral nanoparticle-paclitaxel Dipanjan Pan, Ph.D., Pennsylvania State University  11:05 a.m.  Discussion  11:10 a.m.  Ex vivo vulnerabilities of human gliomas Sunil Krishnan, M.D., Ph.D., UT Health Houston  11:35 a.m.  Title TBA Zigang Dong, M.D., Ph.D., China-US(Henan) Hormel Cancer Institute, University of Zhengzhou  11:55 a.m.  Discussion			
8:55 a.m. Discussion 9:00 a.m. Nanoparticles encapsulated with drugs to reduce stenosis formation in hemodialysis vascular access Gaurav Sahai, Ph.D., Oregon State University 9:20 a.m. Discussion 9:25 a.m. Title TBA Liangfang Zhang, Ph.D., UC San Diego 9:45 a.m. Discussion 9:50 a.m. Title TBA Priyabrata Mukhherjee, Ph.D., Stephenson Cancer Center, Oklahoma 10:10 a.m. Discussion 10:15 a.m. Coffee Break and Exhibits 10:45 a.m. Continuous low-dose cancer chemotherapy with oral nanoparticle-paclitaxel Dipanjan Pan, Ph.D., Pennsylvania State University 11:05 a.m. Discussion 11:10 a.m. Ex vivo vulnerabilities of human gliomas Sunil Krishnan, M.D., Ph.D., UT Health Houston 11:35 a.m. Title TBA Zigang Dong, M.D., Ph.D., China-US(Henan) Hormel Cancer Institute, University of Zhengzhou 11:55 a.m. Discussion	8:35 a.m.	, , , , , , , , , , , , , , , , , , , ,	
9:00 a.m.  Nanoparticles encapsulated with drugs to reduce stenosis formation in hemodialysis vascular access Gaurav Sahai, Ph.D., Oregon State University  9:20 a.m.  Discussion  Title TBA Liangfang Zhang, Ph.D., UC San Diego  9:45 a.m.  Discussion  Title TBA Priyabrata Mukhherjee, Ph.D., Stephenson Cancer Center, Oklahoma  10:10 a.m.  Discussion  10:15 a.m.  Coffee Break and Exhibits  Continuous low-dose cancer chemotherapy with oral nanoparticle-paclitaxel Dipanjan Pan, Ph.D., Pennsylvania State University  11:05 a.m.  Discussion  11:10 a.m.  Ex vivo vulnerabilities of human gliomas Sunil Krishnan, M.D., Ph.D., UT Health Houston  11:30 a.m.  Discussion  Title TBA Zigang Dong, M.D., Ph.D., China-US(Henan) Hormel Cancer Institute, University of Zhengzhou  Discussion  Discussion			
vascular access Gaurav Sahai, Ph.D., Oregon State University  9:20 a.m.  Discussion  9:25 a.m.  Title TBA Liangfang Zhang, Ph.D., UC San Diego  9:45 a.m.  Discussion  7:tlle TBA Priyabrata Mukhherjee, Ph.D., Stephenson Cancer Center, Oklahoma  10:10 a.m.  Discussion  10:15 a.m.  Coffee Break and Exhibits  Continuous low-dose cancer chemotherapy with oral nanoparticle-paclitaxel Dipanjan Pan, Ph.D., Pennsylvania State University  11:05 a.m.  Discussion  11:10 a.m.  Ex vivo vulnerabilities of human gliomas Sunil Krishnan, M.D., Ph.D., UT Health Houston  11:30 a.m.  Discussion  Title TBA Zigang Dong, M.D., Ph.D., China-US(Henan) Hormel Cancer Institute, University of Zhengzhou  11:55 a.m.  Discussion			
Gaurav Sahai, Ph.D., Oregon State University  9:20 a.m.  Discussion  9:25 a.m.  Title TBA  Liangfang Zhang, Ph.D., UC San Diego  9:45 a.m.  Discussion  7:title TBA  Priyabrata Mukhherjee, Ph.D., Stephenson Cancer Center, Oklahoma  10:10 a.m.  Discussion  10:15 a.m.  Coffee Break and Exhibits  10:45 a.m.  Continuous low-dose cancer chemotherapy with oral nanoparticle-paclitaxel Dipanjan Pan, Ph.D., Pennsylvania State University  11:05 a.m.  Discussion  Ex vivo vulnerabilities of human gliomas  Sunil Krishnan, M.D., Ph.D., UT Health Houston  11:30 a.m.  Discussion  Title TBA  Zigang Dong, M.D., Ph.D., China-US(Henan) Hormel Cancer Institute, University of Zhengzhou  Discussion	9:00 a.m.		
9:20 a.m. Discussion  9:25 a.m. Title TBA Liangfang Zhang, Ph.D., UC San Diego  9:45 a.m. Discussion  9:50 a.m. Title TBA Priyabrata Mukhherjee, Ph.D., Stephenson Cancer Center, Oklahoma  10:10 a.m. Discussion  10:15 a.m. Coffee Break and Exhibits  10:45 a.m. Continuous low-dose cancer chemotherapy with oral nanoparticle-paclitaxel Dipanjan Pan, Ph.D., Pennsylvania State University  11:05 a.m. Discussion  11:10 a.m. Ex vivo vulnerabilities of human gliomas Sunil Krishnan, M.D., Ph.D., UT Health Houston  11:30 a.m. Discussion  11:35 a.m. Title TBA Zigang Dong, M.D., Ph.D., China-US(Henan) Hormel Cancer Institute, University of Zhengzhou  11:55 a.m. Discussion			
9:25 a.m.  Title TBA Liangfang Zhang, Ph.D., UC San Diego  9:45 a.m.  Discussion  7:tle TBA Priyabrata Mukhherjee, Ph.D., Stephenson Cancer Center, Oklahoma  10:10 a.m.  Discussion  10:15 a.m.  Coffee Break and Exhibits  Continuous low-dose cancer chemotherapy with oral nanoparticle-paclitaxel Dipanjan Pan, Ph.D., Pennsylvania State University  11:05 a.m.  Discussion  11:10 a.m.  Ex vivo vulnerabilities of human gliomas Sunil Krishnan, M.D., Ph.D., UT Health Houston  11:30 a.m.  Discussion  Title TBA Zigang Dong, M.D., Ph.D., China-US(Henan) Hormel Cancer Institute, University of Zhengzhou  11:55 a.m.  Discussion	0.00		
Liangfang Zhang, Ph.D., UC San Diego  9:45 a.m. Discussion  9:50 a.m. Title TBA Priyabrata Mukhherjee, Ph.D., Stephenson Cancer Center, Oklahoma  10:10 a.m. Discussion  10:45 a.m. Coffee Break and Exhibits  10:45 a.m. Continuous low-dose cancer chemotherapy with oral nanoparticle-paclitaxel Dipanjan Pan, Ph.D., Pennsylvania State University  11:05 a.m. Discussion  11:10 a.m. Ex vivo vulnerabilities of human gliomas Sunil Krishnan, M.D., Ph.D., UT Health Houston  11:30 a.m. Discussion  11:35 a.m. Title TBA Zigang Dong, M.D., Ph.D., China-US(Henan) Hormel Cancer Institute, University of Zhengzhou  11:55 a.m. Discussion			
9:45 a.m. Discussion Title TBA Priyabrata Mukhherjee, Ph.D., Stephenson Cancer Center, Oklahoma 10:10 a.m. Discussion  10:15 a.m. Coffee Break and Exhibits Continuous low-dose cancer chemotherapy with oral nanoparticle-paclitaxel Dipanjan Pan, Ph.D., Pennsylvania State University  11:05 a.m. Discussion Ex vivo vulnerabilities of human gliomas Sunil Krishnan, M.D., Ph.D., UT Health Houston  11:30 a.m. Discussion Title TBA Zigang Dong, M.D., Ph.D., China-US(Henan) Hormel Cancer Institute, University of Zhengzhou  11:55 a.m. Discussion	9:25 a.m.		
9:50 a.m. Title TBA Priyabrata Mukhherjee, Ph.D., Stephenson Cancer Center, Oklahoma  10:10 a.m. Discussion  10:15 a.m. Coffee Break and Exhibits  Continuous low-dose cancer chemotherapy with oral nanoparticle-paclitaxel Dipanjan Pan, Ph.D., Pennsylvania State University  11:05 a.m. Discussion  Ex vivo vulnerabilities of human gliomas Sunil Krishnan, M.D., Ph.D., UT Health Houston  11:30 a.m. Discussion  Title TBA Zigang Dong, M.D., Ph.D., China-US(Henan) Hormel Cancer Institute, University of Zhengzhou  11:55 a.m. Discussion	0.45 a.m		
Priyabrata Mukhherjee, Ph.D., Stephenson Cancer Center, Oklahoma  10:10 a.m. Discussion  10:15 a.m. Coffee Break and Exhibits  10:45 a.m. Continuous low-dose cancer chemotherapy with oral nanoparticle-paclitaxel Dipanjan Pan, Ph.D., Pennsylvania State University  11:05 a.m. Discussion  11:10 a.m. Ex vivo vulnerabilities of human gliomas Sunil Krishnan, M.D., Ph.D., UT Health Houston  11:30 a.m. Discussion  11:35 a.m. Title TBA Zigang Dong, M.D., Ph.D., China-US(Henan) Hormel Cancer Institute, University of Zhengzhou  11:55 a.m. Discussion			
10:10 a.m. Discussion  10:15 a.m. Coffee Break and Exhibits  10:45 a.m. Continuous low-dose cancer chemotherapy with oral nanoparticle-paclitaxel Dipanjan Pan, Ph.D., Pennsylvania State University  11:05 a.m. Discussion  11:10 a.m. Ex vivo vulnerabilities of human gliomas Sunil Krishnan, M.D., Ph.D., UT Health Houston  11:30 a.m. Discussion  11:35 a.m. Title TBA Zigang Dong, M.D., Ph.D., China-US(Henan) Hormel Cancer Institute, University of Zhengzhou  11:55 a.m. Discussion	9:50 a.m.		
10:15 a.m. Coffee Break and Exhibits  10:45 a.m. Continuous low-dose cancer chemotherapy with oral nanoparticle-paclitaxel Dipanjan Pan, Ph.D., Pennsylvania State University  11:05 a.m. Discussion  Ex vivo vulnerabilities of human gliomas Sunil Krishnan, M.D., Ph.D., UT Health Houston  11:30 a.m. Discussion  Title TBA Zigang Dong, M.D., Ph.D., China-US(Henan) Hormel Cancer Institute, University of Zhengzhou  11:55 a.m. Discussion	10·10 a m		
10:45 a.m.  Continuous low-dose cancer chemotherapy with oral nanoparticle-paclitaxel Dipanjan Pan, Ph.D., Pennsylvania State University  11:05 a.m.  Discussion  Ex vivo vulnerabilities of human gliomas Sunil Krishnan, M.D., Ph.D., UT Health Houston  11:30 a.m.  Discussion  Title TBA  Zigang Dong, M.D., Ph.D., China-US(Henan) Hormel Cancer Institute, University of Zhengzhou  11:55 a.m.  Discussion			
Dipanjan Pan, Ph.D., Pennsylvania State University  11:05 a.m. Discussion  Ex vivo vulnerabilities of human gliomas Sunil Krishnan, M.D., Ph.D., UT Health Houston  11:30 a.m. Discussion  Title TBA Zigang Dong, M.D., Ph.D., China-US(Henan) Hormel Cancer Institute, University of Zhengzhou  11:55 a.m. Discussion			
11:05 a.m.Discussion11:10 a.m.Ex vivo vulnerabilities of human gliomas Sunil Krishnan, M.D., Ph.D., UT Health Houston11:30 a.m.Discussion11:35 a.m.Title TBA Zigang Dong, M.D., Ph.D., China-US(Henan) Hormel Cancer Institute, University of Zhengzhou11:55 a.m.Discussion	10.45 a.III.		
11:10 a.m. Ex vivo vulnerabilities of human gliomas Sunil Krishnan, M.D., Ph.D., UT Health Houston  11:30 a.m. Discussion  11:35 a.m. Title TBA Zigang Dong, M.D., Ph.D., China-US(Henan) Hormel Cancer Institute, University of Zhengzhou  11:55 a.m. Discussion	11:05 a m		
Sunil Krishnan, M.D., Ph.D., UT Health Houston  11:30 a.m. Discussion  11:35 a.m. Title TBA Zigang Dong, M.D., Ph.D., China-US(Henan) Hormel Cancer Institute, University of Zhengzhou  11:55 a.m. Discussion			
11:30 a.m. Discussion 11:35 a.m. Title TBA Zigang Dong, M.D., Ph.D., China-US(Henan) Hormel Cancer Institute, University of Zhengzhou 11:55 a.m. Discussion	11.10 a.iii.		
Zigang Dong, M.D., Ph.D., China-US(Henan) Hormel Cancer Institute, University of Zhengzhou  11:55 a.m.  Discussion	11:30 a.m.		
Zigang Dong, M.D., Ph.D., China-US(Henan) Hormel Cancer Institute, University of Zhengzhou  11:55 a.m.  Discussion	11:35 a.m.	Title TBA	
Zhengzhou 11:55 a.m. Discussion			
12:05 p.m. Lunch	11:55 a.m.		
	12:05 p.m.	Lunch	
1:15 p.m. Section II: Welcome and Introduction	1:15 p.m.	Section II: Welcome and Introduction	

	OL LL WILL M.D. M. OI.; D. L. (
	Cheryl L. Willman, M.D., Mayo Clinic Rochester
	Alfredo Quiñones-Hinojosa, M.D., Mayo Clinic Florida
1:20 n m	Vijay Shah, M.D., Mayo Clinic Florida Section III: GBM Microenvironment and novel therapeutics
1:30 p.m.	Chair: Alfredo Quiñones-Hinojosa, M.D., Mayo Clinic Florida
1:35 p.m.	Title TBA
1.00 p.m.	Mitchel Berger, M.D., Ph.D., UCSF
1:55 p.m.	Discussion
2:00 p.m.	The critical role of m6A RNA methylation in cancer cell-brain microenvironment
2.00 p	interaction and brain metastasis
	Suyun Huang, M.D., Ph.D., Virginia Commonwealth University
2:20 p.m.	Discussion
2:25 p.m.	Title TBA
•	Panagiotis Z. Anastasiadis, Ph.D., Mayo Clinic Florida
2:45 p.m.	Discussion
2:50 p.m.	Targeting the Development of Resistance to Stem-Cell Active Drugs in Glioblastoma
	Steven Rosenfeld, M.D., Ph.D., Mayo Clinic Florida
3:10 p.m.	Discussion
3:15 p.m.	Coffee Break and Exhibits
3:45 p.m.	Section IV: Microenvironment and Immune Evasion
	Chair: Vivek Rangnekar, Ph.D., University of Kentucky
3:50 p.m.	Title TBA
	Candace Johnson, Ph.D., Roswell Park Cancer Institute
4:10 p.m.	Discussion
4:15 p.m.	Tumor Microenvironment and cellular tracing
	Nagarajan Kannan, Ph.D., Mayo Clinic Rochester
4:35p.m.	Discussion
4:40 p.m.	Pancreatic cancer tumor microenvironment
F:10 :- :	Daniel D. Billadeau, Ph.D., Mayo Clinic Rochester
5:10 p.m.	Discussion
5:15 p.m.	The good, the bad and the yet to be known about monoclonal anti-CD38 therapy in
	Multiple Myeloma Fabio Malavasi, M.D., University of Torino Medical School, Torino, Italy
5:35 p.m.	Discussion
•	Section V: Martin and Winifred Ehlers Lectureship (Named-Professor Lecture)
5:40 p.m.	Chair: Jennifer J. Westendorf, Ph.D., Mayo Clinic Rochester
5:45 p.m.	Title TBA
	Guillermo A. Ameer, Sc.D., Daniel Hale Williams Professor of Biomedical
	Engineering, McCormick School of Engineering, Professor of Surgery, Feinberg
	School of Medicine
6:10p.m.	Discussion
6:15 p.m.	Section VI: Virtual Poster Session and Networking
7:00 p.m.	Dinner (Supported by Ehlers Lectureship Honoring Dr. Eniola-Adefeso)
	and Health Disparities in Cancer Research and Care – Gaps and Opportunities
	Chair: Cheryl L. Willman, M.D., Chair of Biochemistry & Molecular Biology, Mayo
	Clinic Rochester

	Decellate:
	Panelists:
	Lewis R. Roberts, M.B., Ch.B., Ph.D., Mayo Clinic Rochester
	Folakemi T. Odedina, Ph.D., Mayo Clinic Florida Roxana S. Dronca, M.D., Mayo Clinic Florida
	Candace Johnson, Ph.D., Roswell Park Cancer Institute
9:00 p.m.	ADJOURN – End of Day 1
3.00 p.m.	Friday, December 6, 2024
7:00 a.m.	
	Breakfast and Registration
8:00 a.m.	Section VII: Molecular basis of human diseases
0.10 a m	Chair: Krishnendu Pal, Ph.D., Mayo Clinic Florida
8:10 a.m.	Forkhead (Fox) Transcription Factors in Vascular Formation Tsutomu Kume, Ph.D., Northwestern University
8:30 a.m.	Discussion
8:35 a.m.	Regulation of the PHD/HIF axis in normoxia
0.33 a.III.	Resham Bhattacharya, Ph.D., University of Oklahoma
8:55 a.m.	Discussion
9:00 a.m.	Ultrasmall silica nanoparticles improve anti-tumor pro-inflammatory and cytotoxic
5.00 a.m.	responses in immune suppressive microenvironments.
	Michelle S. Bradbury, M.D., Ph.D., Memorial Sloan Kettering Institute
9:20 a.m.	Discussion
9:25 a.m.	Pancreatic Cancer and pancreatitis
0.20 4.111.	Baoan Ji, Ph.D., Mayo Clinic Florida
9:45 a.m.	Discussion
9:50 a.m.	Neuroblastoma and tumor microenvironment (Young Investigator Talk)
0.00 4	Jane Zhu, Ph.D., Mayo Clinic Rochester
10:05 a.m.	Discussion
10:10 a.m.	Coffee Break and Exhibits
10:35 a.m.	Section VIII: Microenvironment and Cell Signaling
	Chair: Sujit Basu, M.D., Ph.D., Ohio State University
10:40 a.m.	Metabolism and Cancer
	Edward Chini, M.D., Ph.D., Mayo Clinic Florida
11:00 a.m.	Discussion
11:05 a.m.	Cilia as a biomarker of vascular health
	Ramani Ramchandran, Ph.D., Medical College of Wisconsin
11:25 a.m.	Discussion
11:30 a.m.	Microenvironment Dynamic role in Cancer role
	Hellmut Augustin, DVM, Ph.D., Heidelberg University
11:50 a.m.	Discussion
11:55 a.m.	Short Talk from Abstract (not accredited)
12:00 p.m.	Lunch
1:00 p.m.	Section IX: Special Keynote Lecture
	Chair: Asher Chanan-Khan, MD. Mayo Clinic Jacksonville
1:05 p.m.	Title TBA
	Arul M. Chinnaiyan, M.D., Ph.D., University of Michigan
1:30 p.m.	Discussion

Section X: Microenvironment and Cell Therapy
Chair: Hiren Banerjee, M.D., Elizabeth City State University, NC
Title TBA Sanjay Misra, M.D., Mayo Clinic Rochester
Discussion
Endometriosis and Endometrial Cancer: Immune infiltrating cells
Khashayarsha Khazaie, Ph.D., D.Sc., Mayo Clinic Arizona
Discussion
TNBC and immune therapy (Young Clinical Investigator Talk) Pooja Advani, M.D., Mayo Clinic Florida
Discussion
Coffee Break and Exhibits
Section XI: Vascular-Immune biology and cell signaling Chair: Justilien Verline, Ph.D., Mayo Clinic Jacksonville
Liver disease and its microenvironment Vijay Shah, M.D., Mayo Clinic Rochester
Discussion
Pancreatic Cancer and novel therapy
Keping Xie, M.D. Ph.D., South China University of Technology School of Medicine
Discussion
Pancreatic Cancer in invasion (Young Investigator Talk) Gina Razidlo, Ph.D., Mayo Clinic Rochester
Discussion
Young Investigator Travel Award Talks from Abstracts (not accredited)
Section XII: Virtual Poster Session and Reception and Dinner with Cultural Program
ADJOURN – End of Day 2
Saturday, December 7, 2024
Continental Breakfast and Registration
Section XIII: Developing precision therapy targeting microenvironment-immune
pathways from preclinical to clinical steps.
Chair: Roxana Dronca, M.D., Ph.D., Mayo Clinic Florida
TTFields and pancreatic cancer
Hani M. Babiker, M.D., Mayo Clinic Florida
Discussion
Preclinical to Clinical trial in renal cancer
Al Copland, Ph.D., Mayo Clinic Florida
Discussion
Title TBA Azra Raza, M.D., Columbia University
Discussion
Title TBA
Lewis R. Roberts, M.B., Ch.B., Ph.D., Mayo Clinic Rochester
Discussion
Coffee Break and Exhibits

10:20 a.m.	CAR-T cell therapy in solid tumors
	Hong Qin, M.D., Ph.D., Mayo Clinic Florida
10:40 a.m.	Discussion
10:45 a.m.	Immune Therapy Clinical Trials and outcomes
	Keith L. Knutson, Ph.D., Mayo Clinic Florida
11:05 a.m.	Discussion
11:10 a.m.	Section XIV: Folkman Lectureship Forum: New Horizon of Cancer Diagnostic and
	Therapy
	Chairs: Alfredo Quiñones-Hinojosa, M.D., Mayo Clinic Florida
	Vijay Shah, M.D., Mayo Clinic Rochester
11:20 a.m.	Title TBA
	Chad Mirkin, Ph.D., Northwestern University
11:55 p.m.	Discussion
12:10 p.m.	Overview of the symposium
	Asher Chanan-Khan, M.D. and Dev Mukhopadhyay, Ph.D., Mayo Clinic Florida
12:20 p.m.	Vote of Thanks
	Dev Mukhopadhyay, Ph.D., Mayo Clinic Florida
12:30 p.m.	ADJOURN – End of Day 3